Epigenetic Regulator Analysis Service
Inquiry
CD BioSciences offers an integrated, end-to-end suite of Epigenetic Regulator Analysis Services designed to empower your research. From quantifying enzyme activity and mapping genome-wide binding sites to characterizing novel inhibitors and validating disease mechanisms, we provide the precise tools and deep expertise to decipher the epigenetic code and translate discoveries into actionable insights.
Introduction to Epigenetic Regulator
The dynamic regulation of gene expression, beyond the static DNA sequence, is governed by the intricate world of epigenetics. Epigenetic regulators—enzymes and protein complexes that deposit, remove, or interpret chemical marks on DNA and histones—form the central executive suite controlling cellular identity, differentiation, response to environment, and disease pathogenesis. Dysregulation of these regulators is a hallmark of cancer, neurological disorders, metabolic diseases, and aging.
Fig.1 The epigenetic regulatory mechanisms in metabolic diseases. (Wu Y L, et al., 2023)
Mechanism of Epigenetic Regulator
Epigenetic regulation operates through several interconnected layers: DNA methylation, histone post-translational modifications (PTMs), chromatin remodeling, and non-coding RNA-mediated mechanisms. Each layer is orchestrated by specialized "writers," "erasers," and "readers."
DNA Methylation
Primarily involves DNA methyltransferases (DNMTs) adding methyl groups to cytosine, often repressing transcription, and TET enzymes that catalyze active demethylation.
Histone Modifications
A complex language of chemical marks (e.g., acetyl, methyl) added or removed by specific enzymes (e.g., HATs, HDACs, HMTs), which alter chromatin structure and recruit effector proteins.
Chromatin Remodeling
ATP-dependent complexes (e.g., SWI/SNF) physically reposition, evict, or restructure nucleosomes to regulate access to the DNA template for cellular machinery.
Non-coding RNA Regulation
RNAs such as lncRNAs can guide epigenetic writer or eraser complexes to specific genomic loci, serving as scaffolds and targeting signals for chromatin modification.
Our Services
CD BioSciences structures its epigenetic analysis services into focused modules, allowing you to select targeted assays or combine them for a systems-level approach. Our service portfolio is built to provide a holistic view of epigenetic control in your biological system.
Our Comprehensive Service Portfolio
This service provides quantitative analysis of molecular interactions central to epigenetic regulation. We employ a suite of techniques, including SPR, ITC, TR-FRET, Fluorescence Polarization, AlphaScreen, EMSA, and Magnetic Bead Pull-Down, to measure binding affinity, kinetics, and specificity. This is essential for characterizing how reader domains recognize histone marks, how enzymes engage with DNA/RNA substrates, or for evaluating the direct target engagement of novel therapeutic inhibitors in biochemical and cellular contexts, forming a cornerstone for mechanistic and drug discovery research.
This module offers precise enzymatic activity measurements for the key writers and erasers of DNA methylation. Our services encompass the quantitative analysis of DNA Methyltransferases (DNMTs), including isoform-specific activity; TET Dioxygenases that catalyze the iterative oxidation of 5mC during active demethylation; and relevant Base Excision Repair (BER) Glycosylases. These assays are critical for investigating epigenetic mechanisms in development and disease, screening for epigenetic modulators, and studying the functional impact of genetic mutations on this fundamental pathway.
This service focuses on identifying and characterizing the functional interplay between regulatory non-coding RNAs and epigenetic complexes. We utilize two powerful, complementary methodologies: RNA Immunoprecipitation, which captures endogenous ribonucleoprotein complexes under native conditions to identify associated RNAs, and Crosslinking-Immunoprecipitation, which employs in vivo UV crosslinking to map protein-RNA binding sites at nucleotide resolution. Together, they are indispensable for studying how RNAs guide epigenetic regulators to specific genomic loci, mediating transcriptional and post-transcriptional control.
Supported Sample Types
Our flexibility allows us to work with virtually any sample relevant to your research:
- Chemical & Biological Modulators. Small molecule inhibitors/activators, natural product extracts, peptides, oligonucleotides, and recombinant proteins or domains.
- Nucleic Acid Substrates. Unmodified or synthetically modified DNA/RNA oligonucleotides, plasmid DNA, PCR fragments, nucleosome core particles, and chromatinized templates.
- Purified & Recombinant Enzymes/Complexes. Full-length proteins, catalytic domains, mutant variants, and multi-subunit complexes from bacterial, insect, or mammalian expression systems.
- Cellular & Clinical Material. Cultured cell lines (treated or engineered), primary cells, tissue homogenates, nuclear extracts, blood samples, and formalin-fixed paraffin-embedded (FFPE) tissue sections (subject to feasibility).
Diverse Application Scenarios
Target Validation & Mechanistic Biology
Characterize the function of a novel epigenetic factor, define its substrate specificity, and delineate its role in a signaling pathway or developmental process.
Disease Mechanism Elucidation
Profile aberrant epigenetic enzyme activity or chromatin states in patient samples, cell line models, or animal models of disease to identify driver mechanisms.
Drug Discovery & Development
Support epigenetic drug discovery, including detailed biochemical characterization, cellular target engagement assays, and pharmacodynamic biomarker analysis.
Biomarker Discovery
Identify epigenetic enzyme activity levels or specific chromatin accessibility signatures that correlate with disease diagnosis, prognosis, or treatment response.
Toxicology & Safety Pharmacology
Assess the potential off-target effects of drug candidates on a panel of epigenetic regulators to de-risk development.
Service Workflow
Consultation & Project Design
Method Development & Optimization
Sample Preparation & QC
Execution & Multi-Platform Analysis
Data Integration & Reporting
Results Review & Support
Deliverables
Upon project completion, CD BioSciences provides a comprehensive and organized set of deliverables designed to give you actionable data, clear interpretation, and the foundational materials for further research or publication. Our standard delivery package includes:
- Comprehensive Project Report
- Raw & Processed Data Files
- Professional Data Visualizations
- Bioinformatics Analysis Output (if applicable)
- Result Interpretation & Summary Memo
- Complete Methodology Documentation
Our Technical Advantages
- Unmatched Breadth & Depth. We offer one of the most comprehensive portfolios in the industry, allowing for truly integrated multi-omics epigenetic analysis within a single provider.
- Assay Development Expertise. Our experience with challenging targets (e.g., multi-pass transmembrane proteins, large complexes) enables us to develop solutions where standard kits fail.
- Quantitative Rigor. We emphasize kinetics, binding constants (Kd, IC50, Ki), and dose-response relationships, providing data suitable for publication and regulatory submission.
- Translational Focus. Our assays are designed to bridge the gap between basic biochemistry and clinical relevance, supporting biomarker identification and patient stratification strategies.
- Confidentiality & IP Security. Your research is protected by robust confidentiality agreements and secure data management systems.
Frequently Asked Questions (FAQs)
Q1: My research involves a rare cancer model. Can you analyze its unique epigenetic dysregulation?
A: Absolutely. Our services are designed for complex disease models. By combining enzyme activity assays, chromatin accessibility profiling (e.g., ATAC-seq), and interaction studies, we can systematically map the aberrant regulatory network in your specific model and identify key driver mechanisms.
Q2: In drug screening, how can you distinguish if a compound directly affects the target enzyme's activity or works through other indirect pathways?
A: We offer a multi-tiered validation strategy. First, biochemical interaction analysis (e.g., SPR) confirms direct binding. Second, cellular target engagement assays (e.g., CETSA) verify binding within the cellular context. Finally, functional confirmation is achieved by correlating activity data with downstream molecular phenotypes (e.g., changes in specific histone mark levels).
Q3: Can you integrate epigenetic data (e.g., histone modification ChIP-seq) with my transcriptomic data (RNA-seq)?
A: Yes, this is a core component of our advanced bioinformatics services. We can integrate histone modification profiles, chromatin accessibility regions, and differential gene expression data to construct regulatory networks, revealing how epigenetic changes drive gene expression phenotypes.
Q4: How much starting material is required for genome-wide analyses like CLIP-seq or ATAC-seq?
A: Requirements depend on sample type and target abundance. For common cell lines, CLIP-seq typically requires 5x10^7 to 1x10^8 cells, while ATAC-seq needs 5x10^4 to 5x10^5 nuclei. We provide customized optimization plans for specific samples like primary cells or precious tissues.
Q5: What is the difference between DNA methylation (5mC) and hydroxymethylation (5hmC) detection? Which one should I choose?
A: 5-methylcytosine (5mC) is a classical repressive mark. 5-hydroxymethylcytosine (5hmC) is an oxidation product catalyzed by TET enzymes, often associated with active demethylation and specific regulatory functions. Detect 5mC for studying canonical silencing; opt for 5hmC (or both) when investigating active demethylation or its roles in systems like the nervous system or stem cells.
The complexity of the epigenetic landscape demands a partner with specialized tools, integrated capabilities, and strategic vision. CD BioSciences' Epigenetic Regulator Analysis Service is more than a collection of assays; it is a collaborative research engine designed to accelerate your discovery timeline. Whether you are exploring fundamental biology, validating a novel drug target, or developing a companion diagnostic, we provide the precision, reliability, and expert partnership needed to succeed in the dynamic field of epigenetics. Contact us today to design a project that illuminates the regulators shaping your biological system.
Reference
1. Wu Y L, Lin Z J, Li C C, et al. Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study[J]. Signal Transduction and Targeted Therapy, 2023, 8(1): 98.
For Research Use Only. Not for use in diagnostic or therapeutic procedures.
